We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Gut Bacteria Linked to Pulmonary Artery Hypertension

By LabMedica International staff writers
Posted on 11 Mar 2020
Pulmonary arterial hypertension (PAH) is considered a disease of the pulmonary vasculature. More...
Limited progress has been made in preventing or arresting progression of PAH despite extensive efforts.

Previous studies have indicated that PAH could be considered a systemic disease since its pathology involves interplay of multiple organs. This coupled with increasing implication of the gut and its microbiome in chronic diseases, led scientists to hypothesize that patients with PAH exhibit a distinct gut microbiome that contributes to, and predicts, the disease.

A team of scientists from the University of Florida College of Medicine (Gainesville, FL, USA) and their international colleagues evaluated the fecal microbiome of 18 type 1 PAH patients (mean pulmonary arterial pressure, 57.4 ± 16.7 mm Hg) and 13 reference subjects were compared by shotgun metagenomics. The team isolated and sequenced microbiota DNA from stool samples of the patients with PAH and from a reference group who were without a history of cardiopulmonary disease or PAH risk factors.

The investigators reported that their results revealed taxonomic and functional changes in the gut microbial communities of the PAH cohort compared with the reference cohort. Specifically, they noted increases in pathways for the synthesis of arginine, proline and ornithine in patients with PAH as well as increases in groups of bacterial communities associated with trimethylamine/trimethylamine N-oxide (TMA/TMAO) and purine metabolism, whereas the reference cohort displayed increases in butyrate- and propionate-producing bacteria, including Coprococcus, Butyrivibrio, Lachnospiraceae, Eubacterium, Akkermansia and Bacteroides.

The scientists also sought to identify bacteria most strongly associated with PAH by applying random forest modeling to the two cohorts. The model predicted the presence or absence of PAH based on the composition of the gut microbiome with 83% accuracy, as compared with accuracy of 50% or less if no relationship between the gut microbiome and PAH existed. The virome analysis showed enrichment of Enterococcal and relative depletion of Lactococcal phages in the PAH cohort.

The authors concluded that patients with PAH exhibit a unique microbiome profile that has the high predictive potential for PAH. This highlights previously unknown roles of gut bacteria in this disease and could lead to new therapeutic, diagnostic, or management paradigms for PAH.

Mohan Raizada, PhD, distinguished professor in the department of physiology and functional genomics and senior author of the study, said, “We showed for the first time that specific bacteria in the gut are present in people with PAH. While current PAH treatments focus on the lungs, looking at the lung/gut axis could open the door to new therapies centered in the digestive system.” The study was published on February 24, 2020 in the journal Hypertension.

Related Links:
University of Florida College of Medicine


New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Staining Management Software
DakoLink
New
Silver Member
Autoimmune Hepatitis Test
LKM-1-Ab ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.